G
Giorgio Derchi
Researcher at Ente Ospedaliero Ospedali Galliera
Publications - 23
Citations - 607
Giorgio Derchi is an academic researcher from Ente Ospedaliero Ospedali Galliera. The author has contributed to research in topics: Thalassemia & Pulmonary hypertension. The author has an hindex of 10, co-authored 21 publications receiving 525 citations.
Papers
More filters
Journal ArticleDOI
Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies
Giorgio Derchi,Gian Luca Forni,Francesco Formisano,Maria Domenica Cappellini,Renzo Galanello,Giandomenico D'Ascola,Patrizio Bina,Carmelo Magnano,Martina Lamagna +8 more
TL;DR: Data indicate that sildenafil citrate is effective in the treatment of PH in hemoglobinopathies that cannot be treated with alternative oral drugs and is well tolerated long-term at a daily dose of 100 mg, though studies including more patients may uncover toxicities and limitations of efficacy.
Journal ArticleDOI
Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization A Webthal Study
Giorgio Derchi,Renzo Galanello,Patrizio Bina,Maria Domenica Cappellini,Antonio Piga,Maria Eliana Lai,Antonella Quarta,Gavino Casu,Silverio Perrotta,Valeria Pinto,Khaled M. Musallam,Gian Luca Forni +11 more
TL;DR: A multicenter cross-sectional study of 1309 Italian β-thalassemia patients with tricuspid-valve regurgitant jet velocity ≥ 32 m/s on transthoracic echocardiography further underwent right heart catheterization to confirm the diagnosis of pulmonary arterial hypertension.
Journal ArticleDOI
Guideline recommendations for heart complications in thalassemia major.
Tiziana Cogliandro,Giorgio Derchi,Luigi Mancuso,M Carolina Mayer,Bruno Pannone,Alessia Pepe,Marcello Pili,Patrizio Bina,Paolo Cianciulli,Vincenzo De Sanctis,Aurelio Maggio,Hemoglobinopathies (SoSTE) +11 more
TL;DR: These recommendations outline the definition, the follow-up and the treatment of the main heart complications in this group of patients and perform according to the American Cardiology College (ACC) and American Heart Association (AHA) guidelines.
Journal ArticleDOI
Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major
Alessia Pepe,Vincenzo Positano,Marcello Capra,Aurelio Maggio,Carmela Lo Pinto,Anna Spasiano,Gian Luca Forni,Giorgio Derchi,Brunella Favilli,Giuseppe Rossi,Eliana Cracolici,Massimo Midiri,Massimo Lombardi +12 more
TL;DR: In patients with thalassaemia the significant presence of myocardial fibrosis/necrosis seems to be a time-dependent process correlating with cardiovascular risk factors and cardiac complications.
Journal ArticleDOI
Long-term treatment with oral sildenafil in a thalassemic patient with pulmonary hypertension
Roberto Littera,Giorgio La Nasa,Giorgio Derchi,Maria Domenica Cappellini,Christy Y. P. Chang,Licinio Contu +5 more
TL;DR: Pulmonary hypertension (PHT), defined as Doppler peak systolic tricuspid gradient (TG) higher than 30 mmHg, develops in a high percentage of patients with β-thalassemia (10% in thalassemia major and greater than 50% in THA intermedia [TI]).